Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Tendon Transfer Fixation in Patients With Neuromuscular Disease.

Journal of the Pediatric Orthopaedic Society of North America·2026
Same author

Sealing the Deal: Incisional Vacuum Assisted Closure Following Neuromuscular Posterior Spinal Fusion is Associated With a Lower Rate of Infection.

Journal of pediatric orthopedics·2026
Same author

Defining the Impact of Short-Term Surgical Education Courses in Low- and Middle-Income Countries: A Systematic Review.

Journal of surgical education·2025
Same author

Discovery and Optimization of Pyrazine Carboxamide AZ3246, a Selective HPK1 Inhibitor.

Journal of medicinal chemistry·2025
Same author

Discovery of 6-Fluoro-5-{4-[(5-fluoro-2-methyl-3-oxo-3,4-dihydroquinoxalin-6-yl)methyl]piperazin-1-yl}-<i>N</i>-methylpyridine-2-carboxamide (AZD9574): A CNS-Penetrant, PARP1-Selective Inhibitor.

Journal of medicinal chemistry·2024
Same author

Low Prevalence of Anaerobic Bacteria in Pediatric Septic Arthritis Makes Obtaining Anaerobic Cultures of Questionable Value.

Journal of pediatric orthopedics·2024

Related Experiment Video

Updated: May 27, 2026

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody
07:36

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

Reprogramming urokinase into an antibody-recruiting anticancer agent.

Charles E Jakobsche1, Patrick J McEnaney, Andrew X Zhang

  • 1Department of Chemistry, Yale University, New Haven, Connecticut 06520, United States.

ACS Chemical Biology
|November 22, 2011
PubMed
Summary

This study introduces a novel antibody-recruiting molecule (ARM-U) to target cancer cells expressing the urokinase receptor (uPAR). ARM-U effectively directs immune cells to destroy metastatic cancer, offering a new therapeutic strategy.

More Related Videos

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting
11:58

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting

Published on: March 8, 2018

Genetic Encoding of a Non-Canonical Amino Acid for the Generation of Antibody-Drug Conjugates Through a Fast Bioorthogonal Reaction
11:02

Genetic Encoding of a Non-Canonical Amino Acid for the Generation of Antibody-Drug Conjugates Through a Fast Bioorthogonal Reaction

Published on: September 14, 2018

Related Experiment Videos

Last Updated: May 27, 2026

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody
07:36

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting
11:58

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting

Published on: March 8, 2018

Genetic Encoding of a Non-Canonical Amino Acid for the Generation of Antibody-Drug Conjugates Through a Fast Bioorthogonal Reaction
11:02

Genetic Encoding of a Non-Canonical Amino Acid for the Generation of Antibody-Drug Conjugates Through a Fast Bioorthogonal Reaction

Published on: September 14, 2018

Area of Science:

  • Oncology
  • Immunology
  • Biochemistry

Background:

  • Metastatic cancer poses significant treatment challenges.
  • Urokinase-type plasminogen activator receptor (uPAR) is overexpressed on invasive cancer cells, promoting migration.
  • Targeting uPAR offers a potential strategy for cancer immunotherapy.

Purpose of the Study:

  • To develop a novel therapeutic strategy targeting metastatic cancer cells for immune-mediated destruction.
  • To investigate the efficacy of an antibody-recruiting molecule targeting the urokinase receptor (ARM-U).

Main Methods:

  • Design and synthesis of a bifunctional antibody-recruiting molecule (ARM-U).
  • ARM-U covalently links an antibody-binding small molecule to urokinase enzyme's active site.
  • Evaluation of ARM-U's ability to direct antibodies to cancer cells and mediate immune responses (ADCP, ADCC) in vitro.

Main Results:

  • ARM-U successfully targeted cancer cells expressing uPAR.
  • Demonstrated antibody-dependent cellular phagocytosis (ADCP) against multiple human cancer cell lines.
  • Showcased antibody-dependent cellular cytotoxicity (ADCC) mediated by ARM-U.

Conclusions:

  • The developed ARM-U strategy effectively targets metastatic cancer cells for immune destruction.
  • This approach shows potential for novel treatment options against invasive cancers.
  • Further research into ARM-U could lead to new immunotherapeutic interventions.